Cargando…
Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD
INTRODUCTION: We examined the impact of autoantibodies on the erythropoietin receptor (EPOR) in type 2 diabetic patients with chronic kidney disease (CKD). METHODS: A total of 112 Japanese patients with type 2 diabetes who had CKD were enrolled in this study and followed for a mean of 45 months. Ser...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762966/ https://www.ncbi.nlm.nih.gov/pubmed/29340323 http://dx.doi.org/10.1016/j.ekir.2017.08.017 |
_version_ | 1783291801467092992 |
---|---|
author | Hara, Akinori Furuichi, Kengo Koshino, Akihiko Yasuda, Haruka Tran, Trang Thi Thu Iwata, Yasunori Sakai, Norihiko Shimizu, Miho Kaneko, Shuichi Nakamura, Hiroyuki Wada, Takashi |
author_facet | Hara, Akinori Furuichi, Kengo Koshino, Akihiko Yasuda, Haruka Tran, Trang Thi Thu Iwata, Yasunori Sakai, Norihiko Shimizu, Miho Kaneko, Shuichi Nakamura, Hiroyuki Wada, Takashi |
author_sort | Hara, Akinori |
collection | PubMed |
description | INTRODUCTION: We examined the impact of autoantibodies on the erythropoietin receptor (EPOR) in type 2 diabetic patients with chronic kidney disease (CKD). METHODS: A total of 112 Japanese patients with type 2 diabetes who had CKD were enrolled in this study and followed for a mean of 45 months. Sera from these patients were screened for anti-EPOR antibodies using enzyme-linked immunosorbent assays. RESULTS: Anti-EPOR antibodies were detected in 26 patients (23%). Anti-EPOR antibodies were associated with low hemoglobin concentrations and decreased renal function. In patients with biopsy-proven diabetic nephropathy, anti-EPOR antibodies were associated with increased levels of interstitial inflammation. A decrease in renal function was observed more frequently in patients with antibodies than in those without antibodies, and the presence of the antibodies together with well-known clinical parameters, including proteinuria and low glomerular filtration rate, was a significant risk factor for end-stage renal disease. In human tubular epithelial HK-2 cells, IgG fractions containing anti-EPOR antibodies upregulated the expression of monocyte chemoattractant protein-1 mRNA under a high concentration of glucose. CONCLUSION: Anti-EPOR antibodies might be involved in the progression of renal lesions and in the impaired erythropoiesis in type 2 diabetic patients with CKD. Furthermore, the presence of anti-EPOR antibodies may be an additional predictor for end-stage renal disease in type 2 diabetes. |
format | Online Article Text |
id | pubmed-5762966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-57629662018-01-16 Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD Hara, Akinori Furuichi, Kengo Koshino, Akihiko Yasuda, Haruka Tran, Trang Thi Thu Iwata, Yasunori Sakai, Norihiko Shimizu, Miho Kaneko, Shuichi Nakamura, Hiroyuki Wada, Takashi Kidney Int Rep Clinical Research INTRODUCTION: We examined the impact of autoantibodies on the erythropoietin receptor (EPOR) in type 2 diabetic patients with chronic kidney disease (CKD). METHODS: A total of 112 Japanese patients with type 2 diabetes who had CKD were enrolled in this study and followed for a mean of 45 months. Sera from these patients were screened for anti-EPOR antibodies using enzyme-linked immunosorbent assays. RESULTS: Anti-EPOR antibodies were detected in 26 patients (23%). Anti-EPOR antibodies were associated with low hemoglobin concentrations and decreased renal function. In patients with biopsy-proven diabetic nephropathy, anti-EPOR antibodies were associated with increased levels of interstitial inflammation. A decrease in renal function was observed more frequently in patients with antibodies than in those without antibodies, and the presence of the antibodies together with well-known clinical parameters, including proteinuria and low glomerular filtration rate, was a significant risk factor for end-stage renal disease. In human tubular epithelial HK-2 cells, IgG fractions containing anti-EPOR antibodies upregulated the expression of monocyte chemoattractant protein-1 mRNA under a high concentration of glucose. CONCLUSION: Anti-EPOR antibodies might be involved in the progression of renal lesions and in the impaired erythropoiesis in type 2 diabetic patients with CKD. Furthermore, the presence of anti-EPOR antibodies may be an additional predictor for end-stage renal disease in type 2 diabetes. Elsevier 2017-09-08 /pmc/articles/PMC5762966/ /pubmed/29340323 http://dx.doi.org/10.1016/j.ekir.2017.08.017 Text en © 2017 International Society of Nephrology. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Clinical Research Hara, Akinori Furuichi, Kengo Koshino, Akihiko Yasuda, Haruka Tran, Trang Thi Thu Iwata, Yasunori Sakai, Norihiko Shimizu, Miho Kaneko, Shuichi Nakamura, Hiroyuki Wada, Takashi Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD |
title | Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD |
title_full | Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD |
title_fullStr | Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD |
title_full_unstemmed | Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD |
title_short | Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD |
title_sort | clinical and pathological significance of autoantibodies to erythropoietin receptor in type 2 diabetic patients with ckd |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762966/ https://www.ncbi.nlm.nih.gov/pubmed/29340323 http://dx.doi.org/10.1016/j.ekir.2017.08.017 |
work_keys_str_mv | AT haraakinori clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd AT furuichikengo clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd AT koshinoakihiko clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd AT yasudaharuka clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd AT trantrangthithu clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd AT iwatayasunori clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd AT sakainorihiko clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd AT shimizumiho clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd AT kanekoshuichi clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd AT nakamurahiroyuki clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd AT wadatakashi clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd |